2013 Fiscal Year Final Research Report
Clinical application of cancer therapy targeting newly discovered T-cell inhibitory pathways
Project/Area Number |
24791443
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Digestive surgery
|
Research Institution | Nara Medical University |
Principal Investigator |
MIGITA Kazuhiro 奈良県立医科大学, 医学部附属病院, 研究員 (40570990)
|
Project Period (FY) |
2012-04-01 – 2014-03-31
|
Keywords | 食道癌 / 免疫療法 / HVEM |
Research Abstract |
We investigated the functions of herpesvirus entry mediator (HVEM) in vitro and in vivo using the small interfering RNA (siRNA) silencing technique. HVEM gene silencing significantly inhibited cancer cell proliferation through cell cycle arrest in vitro. HVME gene silencing significantly inhibited tumor growth in mice models. The percentage of Ki-67-positive cells was found to be significantly decreased in tumors treated with HVEM siRNA compared with control specimens. In tumors treated with HVEM siRNA, CD8+ lymphocytes infiltrating into the surrounding are of the tumor were found to be significantly more abundant compared with control specimens. The antitumor effect of HVEM blockade was associated with reduced cell proliferation activity and the induction of CD8+ cells.
|
-
[Journal Article] Significant involvement of herpesvirus entry mediator in human esophageal squamous cell carcinoma2014
Author(s)
Migita K, Sho M, Shimada K, Yasuda S, Yamato I, Takayama T, Matsumoto S, Wakatsuki K, Hotta K, Tanaka T, Ito M, Konishi N, Nakajima Y
-
Journal Title
Cancer
Volume: 120
Pages: 808-17
-